Quotes 5-day view Delayed Japan Exchange
06/27/2022
06/28/2022
06/29/2022
06/30/2022
07/01/2022
Date
5620(c)
5712(c)
5800(c)
5725(c)
5691(c)
Last
851 000
813 000
1 479 700
1 156 000
783 500
Volume
+1.06%
+1.64%
+1.54%
-1.29%
-0.59%
Change
Estimated financial data (e) JPY USD
Sales 2022
734 B
5 430 M
5 430 M
Net income 2022
56 199 M
416 M
416 M
Net cash position 2022
143 B
1 060 M
1 060 M
P/E ratio 2022
27,5x
Yield 2022
2,81%
Sales 2023
704 B
5 203 M
5 203 M
Net income 2023
50 890 M
376 M
376 M
Net cash position 2023
226 B
1 671 M
1 671 M
P/E ratio 2023
31,6x
Yield 2023
2,83%
Capitalization
1 632 B
12 070 M
12 070 M
EV / Sales 2022
2,03x
EV / Sales 2023
2,00x
Nbr of Employees
11 322
Free-Float
87,9%
Eisai Company specializes in the manufacturing and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical products (87.7%): prescribed drugs, health products, etc.;
- other (12.3%): food additives, chemical products, etc.
Net sales are distributed geographically as follows: Japan (46.2%), Europe (19.5%), Americas (15.5%), China (10.3%) and other (8.4%).
Ratings of Eisai Co., Ltd.
All news about EISAI CO., LTD.
News in other languages on EISAI CO., LTD.
Analyst Recommendations on EISAI CO., LTD.
Biogen CEO to step down; drugmaker pulls back on Alzheimer's drug Aduhelm
Duration :
Auto.
2 months
3 months
6 months
9 months
1 year
2 years
5 years
10 years
Max.
Period :
Day
Week
Technical analysis trends EISAI CO., LTD.
Short Term Mid-Term Long Term Trends Bullish Neutral Bearish
Income Statement Evolution
Please enable JavaScript in your browser's settings to use dynamic charts.
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
5 691,00 JPY
Average target price
5 784,62 JPY
Spread / Average Target
1,64%
Please enable JavaScript in your browser's settings to use dynamic charts.